What science says about therapeutic fasting, periodic fasting and longevity: potential benefits, risks, contraindications and how supervised protocols work.
When people search for therapeutic fasting and longevity, the real question is not whether stopping food “rejuvenates” the body. The useful question is whether a defined period of food restriction can improve metabolism, inflammation and healthspan markers without causing hypoglycaemia, low blood pressure, muscle loss, food anxiety or unsafe refeeding.
The central point is simple: fasting is not a religion or a discipline contest. In longevity medicine it only makes sense if it improves metabolic health without compromising safety or lean mass. Before talking about prolonged fasting benefits, we need to separate science, commercial enthusiasm and clinical context.
At Progevita, we read fasting as a possible intervention within personalised preventive medicine: body composition, muscle mass, glucose, insulin, lipids, ApoB, blood pressure, inflammation, kidney and liver function, medication, sleep, stress and goals. Without that map, fasting for several days is guesswork.
Evidence review note: updated in May 2026 using Longo 2021, De Cabo and Mattson 2019, Cochrane 2026, NICE CG32, fasting-mimicking diet trials and fasting therapy guidance. This is educational content; it does not replace individual medical assessment or medication review.
What therapeutic fasting is, and what it is not
Therapeutic fasting is a time-limited food restriction protocol with a defined goal: improving metabolic markers, preparing an intervention, reducing digestive load, supporting visceral fat loss or triggering cellular signals studied in aging biology. It can range from 24 hours to several days, with or without small amounts of broth or foods designed to mimic fasting.
It is not a “toxin cleanse”. The liver, kidneys, gut and lymphatic system already do that work. It is also not a longevity guarantee. Longo and colleagues, in Nature Aging (2021, PMID: 35310455), distinguish intermittent fasting lasting 12-48 hours from periodic fasting lasting 2-7 days, and make clear that many molecular pathways are promising but human clinical effects are still being worked out.
The expert-panel update of fasting therapy consensus guidelines published in 2013 (PMID: 24434758) treats medical fasting as a defined intervention with indications, methods and quality criteria. Its safety message is direct: when fasting is used therapeutically, protocols should be accompanied by trained professionals.
The practical difference from intermittent fasting is intensity. A 12/12 or 16/8 window can be a sustainable habit. A 2-7-day fast affects medication, electrolytes, training, sleep, hunger, blood pressure and the return to food. That is already the territory of a supervised fasting protocol.
Types of fasting: comparison table
| Protocol | Typical duration | Main goal | Supervision | Fits / does not fit |
|---|---|---|---|---|
| 12/12 | 12 hours fasting, 12 eating | Better timing, less night snacking, support sleep and glucose | Usually not needed in healthy adults | Fits as a gentle start; does not fit if used to compensate for binge eating |
| 16/8 | 16 hours fasting, 8 eating | Improve adherence, appetite and selected metabolic markers | Review if medication, low weight, high stress or menstrual disruption exist | Fits selected metabolic profiles; does not fit if it worsens sleep, anxiety or total protein |
| 24 hours | One skipped meal pattern or occasional full day | Metabolic flexibility and occasional calorie control | Recommended with diabetes, hypertension, gout or medication | Fits people already adapted to fasting; not a punishment after overeating |
| Prolonged / periodic fasting | 2-7 days in some protocols | Ketosis, lower insulin/IGF-1, AMPK/mTOR/autophagy signals, short metabolic intervention | Yes, especially beyond 48 hours or with any clinical condition | Fits only after screening; not for frailty, low weight, pregnancy, eating disorders, kidney/liver disease or sensitive medication |
| Fasting-mimicking diet | 5 days per cycle | Mimic fasting signals while providing nutrients: low calorie, low protein, low carbohydrate, unsaturated fat | Worth reviewing with disease, medication or low body weight | Fits if a more tolerable option is needed; it is not identical to not eating and should not be sold as certain rejuvenation |
Fasting and autophagy: longevity mechanisms without confusing mechanism for outcome
Fasting changes the body's metabolic language. As glucose and insulin drop, fat use and ketone production rise. At cellular level, energy sensors such as AMPK activate, growth signalling through mTOR decreases, IGF-1 and sirtuin pathways shift, and repair, stress-resistance and fasting and autophagy programmes become more active.
De Cabo and Mattson's review in New England Journal of Medicine (2019, PMID: 31881139) explains the metabolic switch: moving from glucose-based energy toward fatty acids and ketones. That switch is associated with better insulin sensitivity, lower blood pressure in some trials and less oxidative stress. But a mechanism is not a clinical endpoint. Activating AMPK does not prove that someone will live longer.
Autophagy needs careful wording. It is the system by which cells recycle damaged components. In animal models it is easier to measure than in humans; in people, inferring it from fasting hours or ketones is imperfect. We can say that fasting activates autophagy-related pathways. We should not promise “deep cellular cleaning” or rejuvenation.
There is also hormesis: a short stressor may train adaptive responses. Trouble starts when the stress exceeds the person's adaptive capacity: poor sleep, high cortisol, hard training without energy, low protein, low muscle mass or poorly adjusted medication. In longevity, harder is not always better.
What human evidence shows: biomarkers, biological age and hard outcomes
Human evidence is stronger for intermediate biomarkers than for living longer. The National Institute on Aging states this carefully: calorie restriction and some fasting patterns improve human risk factors, but evidence is not yet enough to recommend these regimens broadly as a longevity strategy.
The 2026 Cochrane review of intermittent fasting in adults with overweight or obesity (PMID: 41692034) adds an important counterweight: compared with regular dietary advice, intermittent fasting may lead to little or no difference in percentage weight loss and quality of life, while evidence on adverse events is very uncertain. Practical translation: fasting is not automatically superior to a sustainable, well-designed nutrition intervention.
In periodic Buchinger-type fasting, an observational study of 1,422 people in a specialised clinic (Wilhelmi de Toledo et al., PLOS ONE, 2019, PMID: 30601864) described 4-21-day fasts with 200-250 kcal/day. Weight, waist circumference, blood pressure, glucose and lipids fell, and adverse effects were reported in less than 1%. Interesting, yes. But it was not a randomised trial, and it happened inside a structured clinical setting.
The fasting mimicking diet longevity evidence is small but relevant. In 2017, Wei et al. (Science Translational Medicine, PMID: 28202779) studied 100 adults using 5-day monthly cycles for 3 months: body weight, trunk fat, blood pressure, IGF-1 and selected risk markers decreased, with no serious adverse effects reported. In 2024, Brandhorst et al. (Nature Communications, PMID: 38378685) analysed two trials: three cycles were associated with lower insulin resistance, lower liver fat, a better lymphoid-to-myeloid ratio and a median 2.5-year reduction in estimated biological age, independent of weight loss.
That biological-age result is striking, which is exactly why it needs sober interpretation. It is a predictive marker, not proof that a person will live 2.5 years longer. And when discussing commercial FMD products, conflicts should be named: USC has licensed intellectual property to L-Nutra, and Valter Longo has declared equity interests. The science can be useful without sounding like an advert. If you want the broader context, read our guide to epigenetic clocks and biological age.
For hard outcomes — heart attacks, cancer, dementia, mortality — evidence does not yet show that therapeutic fasting extends human lifespan. A fair statement is: it may improve biomarkers in selected profiles; it rests on plausible mechanisms; long studies proving lower mortality or longer lifespan are still missing.
Potential benefits: where it can make sense
The most plausible benefits appear in people with insulin resistance, visceral fat, elevated blood pressure, disordered appetite, high triglycerides or low-grade inflammation. Not because fasting is magic, but because it creates periods without high insulin, reduces total intake in some people and can help start a better pattern.
- Metabolism: possible improvements in glucose, insulin and HOMA-IR in selected people.
- Visceral fat: reductions in waist and liver fat in some protocols, especially when followed by Mediterranean-style nutrition, strength training and enough protein.
- Blood pressure: it may fall during fasting; this matters if antihypertensive medication is already in place.
- Inflammation: CRP and inflammatory signals may decrease, but response depends on sleep, stress, body composition and post-fast diet. Our evidence-based anti-inflammatory diet guide covers the daily base.
The limit matters just as much: if someone is already lean, sleeps poorly, trains hard, eats too little protein or has a fragile relationship with food, fasting may make health worse. For longevity, the goal is not eating less. It is better muscle, better glucose, lower inflammation and lower risk, with a life that can be maintained.
Therapeutic fasting risks and contraindications
Therapeutic fasting risks do not mean every fast is dangerous. They mean risk concentrates in specific people and protocols. Common problems include hypoglycaemia, dizziness, low blood pressure, headache, irritability, constipation, sleep disruption, temporary uric-acid rise and lower performance. Serious problems appear with medication, underlying disease or poor refeeding.
Prolonged fasting needs supervision with diabetes, insulin or sulfonylureas, antihypertensives, diuretics, anticoagulants, low body weight, pregnancy or breastfeeding, eating disorders, kidney or liver disease, gout, frailty, older age or complex cardiovascular history. The same applies with arrhythmias, fainting, recent surgery or active cancer unless a specialised medical team has indicated it.
Refeeding matters as much as fasting. After several days of low intake, reintroducing a large meal, alcohol or hard training can cause digestive symptoms, oedema, drops in phosphate, potassium or magnesium and, in vulnerable cases, refeeding syndrome. It is uncommon after short fasts in healthy people, but it is real.
NICE CG32 considers people at risk of refeeding problems if they have eaten little or nothing for more than 5 days, and at high risk when there is very low BMI, major weight loss, more than 10 days with little or no intake, low electrolytes, alcohol misuse or drugs such as insulin, chemotherapy, antacids or diuretics. In those cases, returning to food is not just “breaking the fast”; it needs a plan, thiamine/vitamins, electrolytes and monitoring.
What a supervised protocol looks like
A supervised fasting protocol starts before the first fasting day. At Progevita, the question is not “how many days can you endure?” but “what goal makes sense for your biology?”. Screening should include clinical history, medication, blood pressure, body composition, muscle mass, glucose, insulin/HOMA-IR, HbA1c, lipids/ApoB, kidney and liver function, electrolytes, uric acid, blood count and inflammatory markers when relevant. Our longevity biomarkers guide explains why measurement changes decisions.
- Goal: visceral fat, glucose control, digestive rest, FMD trial or a specific clinical protocol.
- Duration: choose the shortest duration that can provide useful information. Do not start with 5 days if 14/10, 16/8 or 24 hours is enough.
- Hydration and electrolytes: water, sodium and, when appropriate, potassium/magnesium under medical judgment.
- Monitoring: blood pressure, pulse, symptoms, glucose/ketones if metabolic risk exists, and medication review.
- Activity: walking, mobility and light strength; avoid HIIT or long sessions if energy is low.
- Sleep and stress: if fasting clearly worsens sleep, the protocol is adjusted or stopped.
- Refeeding: broth or a light meal, then easy-to-digest protein, vegetables, tolerated carbohydrates and healthy fats.
Fasting, muscle and protein: the non-negotiable point
The big longevity trap is confusing weight loss with health gain. After 40-50, muscle mass is metabolic insurance: it improves insulin sensitivity, protects against frailty, supports energy expenditure and predicts function. If fasting reduces fat but also muscle, the trade is not that attractive.
Any protocol should therefore protect lean mass: resistance training before and after, enough protein during eating windows, planned refeeding and body-composition follow-up. For many adults, a practical daily protein range sits around 1.2-1.6 g/kg/day, adjusted for age, kidney function, activity and goal; athletes or fat-loss phases may need more individual guidance. During long fasts, the aim is not to force training. It is to avoid turning restriction into sarcopenia.
The best fasting protocol is one the patient does not need to repeat compulsively. It should leave better data, better nutrition skills and a better relationship with food.
How Progevita interprets it
Progevita does not treat fasting as dogma. It can belong inside a Detox Reset Path or a metabolic-health strategy, but it is not a universal prescription. For one person, the right choice may be 12/12. For another, Mediterranean anti-inflammatory nutrition. For another, strength training and protein before any fast. For a smaller group, a 2-5-day protocol with medical supervision.
Our approach is integration: biomarkers, body composition, sleep, stress, medication, preferences, goals and follow-up. Fasting can be a tool. Long-term health is not built around one tool; it is built around repeated decisions that lower risk without breaking the person.
FAQ
What is therapeutic fasting?
It is a time-limited food restriction protocol with a clinical or preventive goal. It may last from 24 hours to several days and needs more supervision as duration, medication burden or nutritional vulnerability increase.
Does prolonged fasting activate autophagy?
It can activate autophagy-related pathways such as AMPK and mTOR, but we cannot translate fasting hours into a precise “autophagy percentage” in humans. The signal is plausible; the clinical result depends on context.
How many hours of fasting are needed for metabolic benefits?
Many practical benefits begin with 12-16 hours if that removes late-night snacking, improves glucose and structures meals. Fasts of 24 hours or more may have a different effect profile, but they are not required for everyone.
Are intermittent fasting and therapeutic fasting the same?
No. Intermittent fasting is usually a daily or weekly eating-window pattern. Therapeutic fasting has a more clinical goal, may be prolonged and requires safety review, especially beyond 48 hours.
Is fasting-mimicking diet the same as not eating?
No. It provides calories and nutrients, but in a composition designed to reduce glucose, protein and insulin signalling. It may mimic part of the fasting response, not all of it.
Who should not do prolonged fasting?
People with diabetes or glucose-lowering medication, low body weight, pregnancy or breastfeeding, eating disorders, kidney or liver disease, gout, frailty, older age, complex cardiovascular history or medication that may destabilise without food.
Can fasting cause muscle loss?
Yes. Risk rises with long fasts, low protein, no resistance training and poor refeeding. In longevity medicine, protecting muscle matters more than chasing a lower scale number.
How do you break a fast safely?
Use small meals, hydration, electrolytes when needed and gradual reintroduction. After longer fasts, start with gentle foods, easy-to-digest protein and avoid alcohol or hard training immediately.
Does therapeutic fasting extend lifespan?
It has not been proven in humans. It may improve biomarkers related to metabolic health and biological age, but evidence is not strong enough to claim longer life expectancy.
Conclusion: measure first, then fast if it makes sense
Therapeutic fasting can be useful for longevity when applied with selection, measurement and supervision. It may influence glucose, insulin, ketones, inflammation and cellular pathways such as AMPK, mTOR and autophagy. But it does not replace strength, protein, sleep, mental health, diet quality or preventive medicine.
If you are considering prolonged fasting, start with an assessment: body composition, muscle mass, glucose, insulin, lipids, blood pressure, inflammation, kidney and liver function, medication and goals. If the data suggest it fits, design the protocol. If not, the more longevity-aligned intervention may be better food, strength training and sleep before not eating.
Want to know whether fasting fits your plan? Talk to the Progevita medical team and review your biomarkers before attempting a prolonged fast.
References
- Longo VD et al. Intermittent and periodic fasting, longevity and disease. Nature Aging. 2021. PMID: 35310455.
- de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. New England Journal of Medicine. 2019. PMID: 31881139.
- Brandhorst S et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications. 2024. PMID: 38378685.
- Wei M et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science Translational Medicine. 2017. PMID: 28202779.
- Wilhelmi de Toledo F et al. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLOS ONE. 2019. PMID: 30601864.
- Buchinger A et al. Fasting therapy — an expert panel update of the 2002 consensus guidelines. Forsch Komplementmed. 2013. PMID: 24434758.
- Garegnani LI et al. Intermittent fasting for adults with overweight or obesity. Cochrane Database of Systematic Reviews. 2026. PMID: 41692034.
- NICE. Nutrition support for adults: criteria for refeeding risk. Clinical guideline CG32.
- National Institute on Aging. Can fasting reduce disease risk and slow aging in people? 2024.
- USC Leonard Davis School. Eat less, live longer? The science of fasting and longevity. 2019.